Biomarkers in prostate cancer surveillance and screening: Past, present, and future

K. Clinton Cary, Mathew R. Cooperberg

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease. Current clinical practice has been driven largely by the utilization of prostate-specific antigen (PSA). The lack of specificity of PSA for PCa has led to both unnecessary biopsies and overdiagnosis of indolent cancers. The recent controversial recommendation by the United States Preventive Services Task Force against PCa screening has highlighted the need for novel clinically useful biomarkers. We review the literature on PCa biomarkers in serum, urine, and tissue. While these markers show promise, none seems poised to replace PSA, but rather may augment it. Further validation and consideration of how these novel markers improve clinical outcome is necessary. The discovery of new genetic markers shows promise in stratifying men with aggressive PCa.

Original languageEnglish (US)
Pages (from-to)318-329
Number of pages12
JournalTherapeutic Advances in Urology
Volume5
Issue number6
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Biomarkers
Prostate-Specific Antigen
Advisory Committees
Tumor Biomarkers
Disease Management
Genetic Markers
Urine
Biopsy
Serum
Neoplasms

Keywords

  • Biomarkers
  • cancer screening
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Biomarkers in prostate cancer surveillance and screening : Past, present, and future. / Cary, K. Clinton; Cooperberg, Mathew R.

In: Therapeutic Advances in Urology, Vol. 5, No. 6, 12.2013, p. 318-329.

Research output: Contribution to journalArticle

@article{56ebfea4b4ea4a7fb1dcb6fbb7005b34,
title = "Biomarkers in prostate cancer surveillance and screening: Past, present, and future",
abstract = "The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease. Current clinical practice has been driven largely by the utilization of prostate-specific antigen (PSA). The lack of specificity of PSA for PCa has led to both unnecessary biopsies and overdiagnosis of indolent cancers. The recent controversial recommendation by the United States Preventive Services Task Force against PCa screening has highlighted the need for novel clinically useful biomarkers. We review the literature on PCa biomarkers in serum, urine, and tissue. While these markers show promise, none seems poised to replace PSA, but rather may augment it. Further validation and consideration of how these novel markers improve clinical outcome is necessary. The discovery of new genetic markers shows promise in stratifying men with aggressive PCa.",
keywords = "Biomarkers, cancer screening, prostate cancer",
author = "Cary, {K. Clinton} and Cooperberg, {Mathew R.}",
year = "2013",
month = "12",
doi = "10.1177/1756287213495915",
language = "English (US)",
volume = "5",
pages = "318--329",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Biomarkers in prostate cancer surveillance and screening

T2 - Past, present, and future

AU - Cary, K. Clinton

AU - Cooperberg, Mathew R.

PY - 2013/12

Y1 - 2013/12

N2 - The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease. Current clinical practice has been driven largely by the utilization of prostate-specific antigen (PSA). The lack of specificity of PSA for PCa has led to both unnecessary biopsies and overdiagnosis of indolent cancers. The recent controversial recommendation by the United States Preventive Services Task Force against PCa screening has highlighted the need for novel clinically useful biomarkers. We review the literature on PCa biomarkers in serum, urine, and tissue. While these markers show promise, none seems poised to replace PSA, but rather may augment it. Further validation and consideration of how these novel markers improve clinical outcome is necessary. The discovery of new genetic markers shows promise in stratifying men with aggressive PCa.

AB - The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease. Current clinical practice has been driven largely by the utilization of prostate-specific antigen (PSA). The lack of specificity of PSA for PCa has led to both unnecessary biopsies and overdiagnosis of indolent cancers. The recent controversial recommendation by the United States Preventive Services Task Force against PCa screening has highlighted the need for novel clinically useful biomarkers. We review the literature on PCa biomarkers in serum, urine, and tissue. While these markers show promise, none seems poised to replace PSA, but rather may augment it. Further validation and consideration of how these novel markers improve clinical outcome is necessary. The discovery of new genetic markers shows promise in stratifying men with aggressive PCa.

KW - Biomarkers

KW - cancer screening

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84887784853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887784853&partnerID=8YFLogxK

U2 - 10.1177/1756287213495915

DO - 10.1177/1756287213495915

M3 - Article

AN - SCOPUS:84887784853

VL - 5

SP - 318

EP - 329

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 6

ER -